title: Targeting PI3K in Cancer: Any Good News?
abstract: The phosphatidylinositol 3-kinase (PI3K) signaling pathway regulates several cellular processes and it's one of the most frequently deregulated pathway in human tumors. Given its prominent role in cancer, there is great interest in the development of inhibitors able to target several members of PI3K signaling pathway in clinical trials. These drug candidates include PI3K inhibitors, both pan- and isoform-specific inhibitors, AKT, mTOR, and dual PI3K/mTOR inhibitors. As novel compounds progress into clinical trials, it's becoming urgent to identify and select patient population that most likely benefit from PI3K inhibition. In this review we will discuss individual PIK3CA mutations as predictors of sensitivity and resistance to targeted therapies, leading to use of novel PI3K/mTOR/AKT inhibitors to a more "personalized" treatment.
authors: Molecular Biotechnology Center, University of Turin Turin, Italy.
authors: Miriam
authors: M
authors: Martini
authors: Elisa
authors: E
authors: Ciraolo
authors: Federico
authors: F
authors: Gulluni
authors: Emilio
authors: E
authors: Hirsch
keywords: PI3K; cancer; class II phosphatidylinositol 3-kinase; genetic determinants; therapeutics
references: Carcinogenesis. 2000 May;21(5):857-64
references: 10783304
references: Sci Signal. 2011 Oct 18;4(195):re2
references: 22009150
references: Biochem J. 1997 Aug 15;326 ( Pt 1):139-47
references: 9337861
references: J Clin Oncol. 2012 Jan 20;30(3):282-90
references: 22162589
references: J Biol Chem. 1998 Oct 2;273(40):25987-95
references: 9748276
references: BMC Syst Biol. 2010 Nov 29;4:163
references: 21114830
references: Chemotherapy. 2012;58(4):273-81
references: 23006739
references: Science. 2007 Jul 13;317(5835):239-42
references: 17626883
references: Oncogene. 2006 Oct 26;25(50):6648-59
references: 16702948
references: Biochem Biophys Res Commun. 2003 Jun 20;306(1):139-43
references: 12788079
references: J Biol Chem. 2007 Sep 21;282(38):28226-36
references: 17644513
references: Nat Rev Drug Discov. 2009 Aug;8(8):627-44
references: 19644473
references: J Biol Chem. 1999 May 21;274(21):14529-32
references: 10329640
references: EMBO J. 2002 Oct 1;21(19):5097-108
references: 12356726
references: Cell. 2012 Apr 13;149(2):274-93
references: 22500797
references: Science. 2002 Jul 5;297(5578):63-4
references: 12098689
references: N Engl J Med. 2010 Aug 26;363(9):809-19
references: 20818844
references: Cancer Res. 2010 Mar 15;70(6):2389-96
references: 20197460
references: Nat Med. 2012 Oct;18(10):1560-9
references: 22983395
references: Mol Pharmacol. 2012 Dec;82(6):1230-40
references: 22989521
references: Clin Cancer Res. 2012 Jul 15;18(14):3901-11
references: 22586300
references: Brain Pathol. 2010 Sep;20(5):936-44
references: 20406234
references: Clin Cancer Res. 2011 Nov 1;17(21):6840-6
references: 21890452
references: Mol Cell. 2001 Feb;7(2):443-9
references: 11239472
references: Neoplasia. 2012 Jan;14(1):34-43
references: 22355272
references: Cancer Cell. 2009 Aug 4;16(2):115-25
references: 19647222
references: Mol Med Rep. 2012 Feb;5(2):503-8
references: 22101421
references: Neuro Oncol. 2012 Jul;14(7):819-29
references: 22619466
references: J Clin Invest. 2008 Sep;118(9):3065-74
references: 18725988
references: Postgrad Med. 2010 May;122(3):158-65
references: 20463425
references: Biochem Soc Trans. 2007 Apr;35(Pt 2):211-4
references: 17371240
references: J Pathol. 2005 Jan;205(1):29-40
references: 15586366
references: Cancer Biol Ther. 2012 Nov;13(13):1307-18
references: 22895072
references: Anticancer Res. 2008 Nov-Dec;28(6A):3729-32
references: 19189657
references: Clin Cancer Res. 2012 Jan 1;18(1):184-95
references: 22065080
references: J Med Chem. 2008 Sep 25;51(18):5522-32
references: 18754654
references: PLoS One. 2012;7(6):e39626
references: 22737248
references: Science. 2002 May 31;296(5573):1655-7
references: 12040186
references: Blood. 2005 Aug 1;106(3):1063-6
references: 15840695
references: Clin Cancer Res. 2009 Jun 15;15(12):4147-56
references: 19509167
references: Nat Med. 2004 Aug;10(8):789-99
references: 15286780
references: Leuk Lymphoma. 2010 Jun;51(6):1098-107
references: 20536348
references: Sci Transl Med. 2012 Mar 28;4(127):127rv2
references: 22461643
references: Breast Cancer Res Treat. 2011 Sep;129(2):387-400
references: 21046231
references: Nat Rev Clin Oncol. 2011 Nov 15;9(2):87-97
references: 22083042
references: Nat Rev Mol Cell Biol. 2010 May;11(5):329-41
references: 20379207
references: J Clin Invest. 2010 Aug;120(8):2858-66
references: 20664172
references: Cancer Discov. 2011 Dec;1(7):562-72
references: 22586681
references: J Cell Biol. 2005 Jun 6;169(5):789-99
references: 15928202
references: Leukemia. 2006 Jun;20(6):911-28
references: 16642045
references: Mol Cancer Ther. 2011 Mar;10(3):558-65
references: 21216929
references: Br J Cancer. 2011 Jun 28;105(1):1-8
references: 21654681
references: Mol Cancer Ther. 2009 Aug;8(8):2204-10
references: 19671762
references: PLoS One. 2011;6(9):e25132
references: 21966435
references: Biochem Biophys Res Commun. 2009 Sep 18;387(2):310-5
references: 19591801
references: J Biol Chem. 1996 Jun 7;271(23):13304-7
references: 8663140
references: Carcinogenesis. 2012 Jul;33(7):1270-6
references: 22510280
references: Mol Cell Biol. 2002 Dec;22(24):8580-91
references: 12446777
references: J Int Med Res. 2011;39(4):1319-32
references: 21986133
references: Cancer Res. 2009 Jan 1;69(1):143-50
references: 19117997
references: Science. 2004 Apr 23;304(5670):554
references: 15016963
references: Trends Biochem Sci. 2009 Mar;34(3):115-27
references: 19299143
references: Drug Discov Today. 2010 Feb;15(3-4):88-97
references: 19961955
references: Mol Cell Biol. 2000 Jun;20(11):3817-30
references: 10805725
references: Brain Pathol. 2003 Oct;13(4):507-18
references: 14655756
references: Genes Dev. 2007 Dec 15;21(24):3214-31
references: 18079171
references: Oncogene. 2008 Jul 3;27(29):4086-95
references: 18332865
references: Blood. 2011 Jan 13;117(2):591-4
references: 20959606
references: Clin Cancer Res. 2010 Jan 15;16(2):530-40
references: 20068094
references: Nat Rev Cancer. 2011 Apr;11(4):289-301
references: 21430697
references: Front Oncol. 2012 Aug 31;2:109
references: 22970424
references: Mol Cancer Res. 2008 Apr;6(4):614-23
references: 18403640
references: Cancer Res. 2008 Oct 1;68(19):8022-30
references: 18829560
references: Nat Med. 2008 Dec;14(12):1351-6
references: 19029981
references: Crit Rev Oncol Hematol. 2004 Jun;50(3):197-222
references: 15182826
references: J Pathol. 2011 Jan;223(2):251-61
references: 21125679
references: Biochem Soc Trans. 2003 Feb;31(Pt 1):270-4
references: 12546700
references: Mol Cancer Ther. 2012 Aug;11(8):1747-57
references: 22653967
references: Oncotarget. 2012 Dec;3(12):1566-75
references: 23248156
references: Oncogene. 2008 Mar 20;27(13):1951-60
references: 17952125
references: Biochem J. 2009 Jan 1;417(1):361-70
references: 18976239
references: PLoS One. 2011;6(7):e22769
references: 21829508
references: Nat Rev Drug Discov. 2009 Sep;8(9):709-23
references: 19629074
references: Proc Natl Acad Sci U S A. 2007 Oct 9;104(41):16158-63
references: 17911267
references: Blood. 2006 Jan 15;107(2):642-50
references: 16179367
references: J Neurooncol. 2010 Jan;96(2):169-79
references: 19609742
references: Oncogene. 2012 May 31;31(22):2750-60
references: 21963845
references: Nat Med. 2011 Sep 25;17(10):1298-303
references: 21946537